Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

ClinicalTrials.gov ID: NCT01720537

Public ClinicalTrials.gov record NCT01720537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is to evaluate the safety, tolerability and immunogenicity of single, ascending or multiple fixed subcutaneous and intravenous administrations of PF 05335810 to hypercholesterolemic subjects when added on to a daily statin dose.

Study identification

NCT ID
NCT01720537
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Pfizer
Industry
Enrollment
133 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2012
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013
Last update posted
Dec 3, 2018

2012 – 2013

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Pfizer Investigational Site New Haven Connecticut 06511
Pfizer Investigational Site Miami Florida 33169
Pfizer Investigational Site South Miami Florida 33143
Pfizer Investigational Site Overland Park Kansas 66212
Pfizer Investigational Site Kalamazoo Michigan 49007
Pfizer Investigational Site Cincinnati Ohio 45227
Pfizer Investigational Site San Antonio Texas 78209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Hypercholesterolemia trials

Other public records listing Hypercholesterolemia. Sorted by last update posted; newest first. Not a recommendation.

All Hypercholesterolemia trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01720537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 3, 2018 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01720537 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →